A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Open to people ages 60 years and up

• Vaccination for Neisseria meningitidis.
• Capable of giving signed informed consent.
• Presentation of GA secondary to AMD in at least 1 eye
• The entire GA lesion must be > 1 μm outside of the foveal center

• GA in the study eye due to cause other than AMD.
• Have previously received intravitreal anti-vascular endothelial growth factor injections in study eye for intraocular vascular disease.
• Have previously received any stem cell/gene therapy for any ophthalmological condition in either eye.
• Use of any investigational medicinal product (ie, participation in interventional clinical studies for any ophthalmic indications) or use of any regulatory approved treatment for GA in the study eye regardless of route of administration within the last 3 months or 5 half-lives of the last dose of the investigational or commercial product (whichever is longer).
• Presence of active ocular diseases in the study eye that in the opinion of the Investigator compromises or confounds visual function or interferes with study assessments.
• Known or suspected complement deficiency.
• History or presence of any medical or psychological condition that, in the opinion of the Principal Investigator, would make the patient inappropriate for the study.

• Hypersensitivity to fluorescein sodium for injection, the investigational drug (danicopan) or any of its excipients.

  Note: Additional inclusion/exclusion criteria may apply, per protocol.